BioVie Will Present Clinical Trial Findings in San Diego
The company is set to share results from two Phase 2 studies at the 2026 American Neurological Association Annual Meeting.
Updated on Oct. 14, 2026 in Alzheimer’s
BioVie will present findings from its bezisterim clinical trials during the American Neurological Association Annual Meeting taking place in San Diego from October 17-20, 2026. The company will showcase data from its ongoing work in Long COVID and Parkinson's disease.
Why it matters
These presentations offer insight into the progress of bezisterim, a drug designed to reduce inflammation by modulating pathways including ERK, NFκB, and TNFα. The trial results provide data on the drug's performance in varied patient populations.
The studies include results from the SUNRISE-PD Parkinson's trial with 57 participants and the ADDRESS-LC Long COVID trial which enrolled approximately 200 patients. The ADDRESS-LC study did not reach statistical significance on endpoints in the intent-to-treat population.
The players
BioVie
This Carson City, Nev.-based biopharmaceutical company focuses on developing drugs for neurological and liver conditions.
The details
BioVie will present posters detailing the outcomes of its Phase 2 investigations at the upcoming conference. Bezisterim operates by modulating specific cellular pathways, including ERK, NFκB, and TNFα, to manage inflammation.
Timeline
The American Neurological Association Annual Meeting occurs October 17-20, 2026.
Findings from the Long COVID trial will be presented on October 18, 2026.
Results from the Parkinson's disease trial will be shared on October 19, 2026.
The Big Picture
The American Neurological Association Annual Meeting serves as a central venue for researchers and firms to share recent clinical trial developments. This story follows the established pattern of companies utilizing high-profile professional conferences to disseminate findings from Phase 2 trials.
For patients and medical professionals, these findings clarify the current clinical performance of bezisterim in treating Long COVID and Parkinson's disease. The data helps in understanding the therapeutic potential of inflammation modulation for those currently managing these conditions.
The takeaway
Understanding the results of these trials is essential for evaluating the viability of emerging inflammatory treatments. Patients should consult with their healthcare providers to discuss how these research updates might relate to their specific treatment options.
Further reading
Learn more about the latest research in the field of Alzheimer’s.
